Preclinical evaluation of apoptosis induction by the novel small molecule BCL-2 inhibitor, GX015–070, in ex vivo chronic lymphoid leukemia (CLL) cells

MLA

P. Beauparlant, et al. “Preclinical Evaluation of Apoptosis Induction by the Novel Small Molecule BCL-2 Inhibitor, GX015–070, in Ex Vivo Chronic Lymphoid Leukemia (CLL) Cells.” Journal of Clinical Oncology, vol. 23, June 2005, p. 3149. EBSCOhost, https://doi.org/10.1200/jco.2005.23.16_suppl.3149.

APA

P. Beauparlant, M. Watson, Xiaoduan Weng, J. Viallet, H. J. Olney, D. Soulieres, & M. Sarfati. (2005). Preclinical evaluation of apoptosis induction by the novel small molecule BCL-2 inhibitor, GX015–070, in ex vivo chronic lymphoid leukemia (CLL) cells. Journal of Clinical Oncology, 23, 3149. https://doi.org/10.1200/jco.2005.23.16_suppl.3149

Chicago

P. Beauparlant, M. Watson, Xiaoduan Weng, J. Viallet, H. J. Olney, D. Soulieres, and M. Sarfati. 2005. “Preclinical Evaluation of Apoptosis Induction by the Novel Small Molecule BCL-2 Inhibitor, GX015–070, in Ex Vivo Chronic Lymphoid Leukemia (CLL) Cells.” Journal of Clinical Oncology 23 (June): 3149. doi:10.1200/jco.2005.23.16_suppl.3149.